Drugs / SR13668
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00896207 | Jun 2009 → Mar 2010 | — | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SR13668 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00896207 ↗ |
| Action | Inhibit | “Serine/threonine-protein kinase AKT inhibitor” CHEMBL245030 ↗1“Akt inhibitor SR13668” NCT00896207 ↗ |
| Modality | Small molecule | — CHEMBL245030 ↗ |
| Route | Oral | “Given orally as a single dose” NCT00896207 ↗ |
| Target | AKT1 | “Serine/threonine-protein kinase AKT inhibitor” CHEMBL245030 ↗ |